Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
WHSC1L1
REST API REST API
Homo sapiens
WHSC1L1 is differentially expressed in 272 experiments: 137 organism parts: skin, blood, ... (135 more);, 194 disease states: normal, breast carcinoma, ... (192 more);, 88 cell types 407 cell lines 34 compound treatments and 79 other conditions.
Synonyms FLJ20353, NSD3
Orthologs Whsc1l1 (Mus musculus)   E1C6X8_CHICK (Gallus gallus)   Whsc1l1 (Rattus norvegicus)   WHSC1L1 (Bos taurus)   whsc1l1 (Danio rerio)   WHSC1L1 (Xenopus laevis)   WHSC1L1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term protein binding, regulation of transcription, DNA-dependent, histone methylation, metal ion binding, cell differentiation, cell growth, methyltransferase activity, nucleus, transferase activity, chromosome, chromatin modification, histone-lysine N-methyltransferase activity, zinc ion binding, histone lysine methylation
InterPro Term Znf_PHD-finger, AWS, Znf_PHD, Post-SET_dom, PWWP, SET_dom
UniProt Accession B7ZL11, C9JY66, Q9BZ95, E9PQ95, E9PKA2
Gene-Disease Assocation LEUKEMIA, ACUTE MYELOID; AML
Search EB-eye ENSG00000147548
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-15765, E-GEOD-803, E-GEOD-22541, E-GEOD-6573, ... (28 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-2450, E-MTAB-62, ... (36 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-5823, E-GEOD-19639, E-GEOD-20081, E-GEOD-3529
BT-474
2
E-GEOD-3529, E-GEOD-5823
MCF-10A
2
E-GEOD-14990, E-TABM-420
MOLT4
2
E-MTAB-37, E-MTAB-62
NA18508
1
E-GEOD-19480
MCCAR
1
E-MTAB-37
401 more value(s).


Cell type

studied in E-MEXP-1121, E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-GEOD-21909, ... (49 experiments)

Factor Value U/D Experiments
fibroblast
2
E-GEOD-3920, E-GEOD-26672
epithelial cell
1
2
E-MEXP-2034, E-GEOD-4483, E-MEXP-1121
721 B lymphoblast
2
1
E-AFMX-5
purified CLL B cells from peripheral blood
1
E-GEOD-22529
adipose-derived stem cell
1
E-MEXP-1216
human foreskin fibroblast
1
E-GEOD-18265
82 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-4172, E-GEOD-15960, E-GEOD-1577, E-MEXP-1121, ... (53 experiments)

Factor Value U/D Experiments
cervical carcinoma
3
E-MTAB-37, E-GEOD-5823, E-MTAB-62
glioblastoma
3
E-GEOD-4290, E-GEOD-4412, E-MTAB-37
acute lymphoblastic leukemia
2
E-MTAB-62, E-MTAB-37
adrenocortical carcinoma
2
E-GEOD-10927, E-TABM-311
lung adenocarcinoma
2
E-MTAB-37, E-MTAB-62
melanoma
2
E-MTAB-37, E-MTAB-62
188 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-15205, E-TABM-782, E-GEOD-3720, E-GEOD-5824, ... (21 experiments)

Factor Value U/D Experiments
none
3
4
E-GEOD-20719, E-MEXP-1958, E-GEOD-5824, E-TABM-782, E-GEOD-7307, ... (7 experiments)
MIG control
1
E-GEOD-15811
TTA
1
E-MEXP-2590
bacterial endotoxin
1
E-GEOD-3284
sapphyrin PCI-2052
1
E-GEOD-6400
dimethyl sulfoxide
1
E-GEOD-5824
28 more value(s).


Age at diagnosis

studied in E-GEOD-3494

Factor Value U/D Experiments
37
2
1
E-GEOD-3494


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-17189, E-GEOD-19348, E-MEXP-1251, ... (7 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-MEXP-2359, E-GEOD-6236, E-GEOD-2666, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-7788, E-GEOD-3325, E-GEOD-22541, E-GEOD-22148, ... (6 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720, E-GEOD-4086

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, E-MTAB-108, ... (6 experiments)

Genotype
studied in E-TABM-763, E-GEOD-17476, E-GEOD-21750, E-MEXP-421, E-GEOD-2292, ... (10 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-MEXP-2657, E-GEOD-20540, E-TABM-440, E-GEOD-1692, ... (14 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-MEXP-2069, E-TABM-26, ... (34 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-MEXP-561, E-GEOD-17400

Initial distant metastases
studied in E-GEOD-22541

Injury
studied in E-GEOD-19743

Labeling
studied in E-LGCL-5

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-22541

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Performer
studied in E-GEOD-2004, E-LGCL-5

Phenotype
studied in E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, E-MEXP-1403

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-22097, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343

Replicate
studied in E-GEOD-10797, E-GEOD-19330, E-GEOD-18791, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, E-MEXP-1315, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400

Sex
studied in E-GEOD-1643, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Tissue
studied in E-GEOD-30573

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-33562, E-GEOD-16837, E-GEOD-19246, E-GEOD-19815, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-22541

Tumor size
studied in E-GEOD-6532

Vehicle
studied in E-GEOD-5258

Processing time: 0.35 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM